Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis
Approved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This study aims to describe prescription patterns and rec...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-03-01
|
| Series: | Biology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2079-7737/11/3/422 |
| _version_ | 1797447068505079808 |
|---|---|
| author | Michèle Hoffmann Stefanie Hayoz Berna C. Özdemir |
| author_facet | Michèle Hoffmann Stefanie Hayoz Berna C. Özdemir |
| author_sort | Michèle Hoffmann |
| collection | DOAJ |
| description | Approved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This study aims to describe prescription patterns and recurrence and toxicity rates of adjuvant-treated melanoma patients from the Cancer Center of the University Hospital Bern, Switzerland. One hundred and nine patients with an indication for adjuvant treatment were identified. Five (4.6%) had contraindications and, as such, were not proposed any adjuvant treatment, while 10 patients (9.2%) declined treatment. BRAF status was known for 91 (83.5%) patients. Of 40 (36.7%) patients with BRAF V600E/K melanoma, pembrolizumab was prescribed to 18 (45.0%), nivolumab to 16 (40.0%), and dabrafenib/trametinib to three (7.5%) patients. Grade 3–4 toxicity was reported in 18.9% and 16.7% of all the patients treated with pembrolizumab and nivolumab, respectively. No toxicities were observed for dabrafenib/trametinib. Thirty-eight percent of the patients treated with pembrolizumab and 40.0% of those treated with nivolumab relapsed. No relapses were reported for dabrafenib/trametinib. Prescription patterns indicate a clear preference for adjuvant ICI treatment. |
| first_indexed | 2024-03-09T13:50:32Z |
| format | Article |
| id | doaj.art-daf74a75f6c74d5cb729eff1b1a74f00 |
| institution | Directory Open Access Journal |
| issn | 2079-7737 |
| language | English |
| last_indexed | 2024-03-09T13:50:32Z |
| publishDate | 2022-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology |
| spelling | doaj.art-daf74a75f6c74d5cb729eff1b1a74f002023-11-30T20:51:59ZengMDPI AGBiology2079-77372022-03-0111342210.3390/biology11030422Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center AnalysisMichèle Hoffmann0Stefanie Hayoz1Berna C. Özdemir2Department of Medical Oncology, Inselspital Bern, Bern University Hospital, University of Bern, 3012 Bern, SwitzerlandSwiss Group for Clinical Cancer Research, 3008 Bern, SwitzerlandDepartment of Medical Oncology, Inselspital Bern, Bern University Hospital, University of Bern, 3012 Bern, SwitzerlandApproved adjuvant treatment options for stage III melanoma are the immune checkpoint inhibitors (ICI) pembrolizumab and nivolumab, and in presence of a BRAF V600E/K mutation additionally dabrafenib in combination with trametinib (BRAFi/MEKi). This study aims to describe prescription patterns and recurrence and toxicity rates of adjuvant-treated melanoma patients from the Cancer Center of the University Hospital Bern, Switzerland. One hundred and nine patients with an indication for adjuvant treatment were identified. Five (4.6%) had contraindications and, as such, were not proposed any adjuvant treatment, while 10 patients (9.2%) declined treatment. BRAF status was known for 91 (83.5%) patients. Of 40 (36.7%) patients with BRAF V600E/K melanoma, pembrolizumab was prescribed to 18 (45.0%), nivolumab to 16 (40.0%), and dabrafenib/trametinib to three (7.5%) patients. Grade 3–4 toxicity was reported in 18.9% and 16.7% of all the patients treated with pembrolizumab and nivolumab, respectively. No toxicities were observed for dabrafenib/trametinib. Thirty-eight percent of the patients treated with pembrolizumab and 40.0% of those treated with nivolumab relapsed. No relapses were reported for dabrafenib/trametinib. Prescription patterns indicate a clear preference for adjuvant ICI treatment.https://www.mdpi.com/2079-7737/11/3/422melanomaadjuvant treatmentBRAF inhibitoranti-PD1immune checkpoint inhibitorprescription pattern |
| spellingShingle | Michèle Hoffmann Stefanie Hayoz Berna C. Özdemir Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis Biology melanoma adjuvant treatment BRAF inhibitor anti-PD1 immune checkpoint inhibitor prescription pattern |
| title | Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis |
| title_full | Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis |
| title_fullStr | Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis |
| title_full_unstemmed | Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis |
| title_short | Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis |
| title_sort | prescription patterns recurrence and toxicity rates of adjuvant treatment for stage iii iv melanoma a real world single center analysis |
| topic | melanoma adjuvant treatment BRAF inhibitor anti-PD1 immune checkpoint inhibitor prescription pattern |
| url | https://www.mdpi.com/2079-7737/11/3/422 |
| work_keys_str_mv | AT michelehoffmann prescriptionpatternsrecurrenceandtoxicityratesofadjuvanttreatmentforstageiiiivmelanomaarealworldsinglecenteranalysis AT stefaniehayoz prescriptionpatternsrecurrenceandtoxicityratesofadjuvanttreatmentforstageiiiivmelanomaarealworldsinglecenteranalysis AT bernacozdemir prescriptionpatternsrecurrenceandtoxicityratesofadjuvanttreatmentforstageiiiivmelanomaarealworldsinglecenteranalysis |